POPULARITY
7 episodes with noninvasive
7 episodes with noninvasive
5 episodes with noninvasive
4 episodes with noninvasive
4 episodes with noninvasive
3 episodes with noninvasive
3 episodes with noninvasive
3 episodes with noninvasive
2 episodes with noninvasive
Dr. Christine Daigle is a child and adolescent clinical neuropsychologist and clinical psychologist whose work includes brain-computer interface, translating brain signals into commands to control technology. She's been doing children's psychology for 17 years, specializing in developmental disabilities, autism, learning challenges, and mental health. Key points.
In this episode of the HVAC Know It All Podcast, host Gary McCreadie continues his engaging discussion with Jennifer Manzo, a key innovator in the HVAC sector and chief trainer for SkillCat.In Part 2 of their conversation, they delve into Jennifer's unique experiences as a female trainer in a predominantly male industry, her approach to virtual training, and her active role in fostering a supportive community through initiatives like the HVAC Chicks Coalition. They explore how these efforts contribute to better training practices and enhance the overall dynamics within the HVAC field. Jennifer Manzo shares her comprehensive approach to elevating the competencies of both new and experienced technicians through tailored training sessions that cater to various skill levels. She discusses the inherent challenges and significant strides toward gender inclusivity within the traditionally male-dominated HVAC industry. The episode covers everything from HVAC fundamentals to advanced diagnostics, aiming to build a skilled and diverse workforce. Jennifer highlights the impact of community initiatives like her coalition, which provides free technical support and training, showcasing how collaboration can elevate industry standards. In this part of the discussion, Jennifer outlines how their clients generally fall into two pivotal categories: Educate: This group consists of technicians and HVAC professionals eager to advance their technical skills and industry understanding, from foundational concepts to complex diagnostics, all facilitated through expert-led training sessions and community-driven support initiatives. Empower: Individuals within the HVAC industry who strive to boost their professional standing, effectively navigate gender dynamics, and make a positive impact on the community via inclusive and supportive educational platforms. Jennifer discusses enhancing technician training and promoting gender inclusivity through community support, specialized knowledge, and mentorship. The episode offers practical tips for HVAC professionals to grow their skills and advance their careers. Expect to Learn: Jennifer Manzo's innovative training approaches with SkillCat, spanning from basic HVAC fundamentals to sophisticated diagnostic techniques suitable for technicians at all levels. The impact of gender dynamics on professional development and community within the HVAC industry, along with strategies to foster inclusivity. The role of a specialized expert coalition in resolving intricate HVAC challenges effectively and efficiently. The significant advantages of community-led initiatives that enhance industry collaboration and provide educational opportunities. Episode Highlights: [00:00] - Introduction to Part 2 with Guest Jennifer Manzo from SkillCat. [02:00] - The Importance of HVAC Community & Tech Support [03:38] - Challenges with Manufacturer Support & Training [06:38] - What is Noninvasive Testing? [09:53] - Why Technicians Should Stop Gauging Up on Every Service Call [13:42] - The Role of Measure Quick & Smart Tools [18:32] - How Thermal Imaging Helps HVAC Professionals [20:57] - Entrepreneurial Freedom: The Power of Saying No [23:44] - Real-World HVAC Scenarios & Lessons Learned [24:56] - Jennifer's Podcast & Future Collaboration. This Episode is Kindly Sponsored by: Master: www.master.ca Cintas: www.cintas.com/hvacknowitall Supply House: www.supplyhouse.com Cool Air Products: www.coolairproducts.net Lambert Insurance Services: www.lambert-ins.com Follow the Guest Jennifer Manzo on: LinkedIn: https://www.linkedin.com/in/hvachicks-jennifer-206832280/ SkillCat: https://www.linkedin.com/company/skillcat/ Follow the Host: LinkedIn: https://www.linkedin.com/in/gary-mccreadie-38217a77/ Website: https://www.hvacknowitall.com Facebook: https://www.facebook.com/HVAC-Know-It-All-2/ Instagram: https://www.instagram.com/hvacknowitall1/
Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma, has developed a novel, non-invasive treatment for basal cell carcinoma, the most common form of skin cancer. This cost-effective transdermal Skinject patch delivers a chemotherapeutic agent applied in a clinician's office over three sessions to remove the lesion, potentially avoiding the need for Mohs surgery, the current standard of care. Medicus is incorporating AI and advanced imaging techniques in its clinical trials to improve diagnosis and monitoring of the treatment's effectiveness. Raza explains, "The gold standard to treat basal cell carcinoma of the skin is surgical intervention, generally speaking, all solid tumors to eliminate cancer if it is caught in the early stage. The treatment regimen is that you surgically take the malignant cells out. The same is true for basal cell carcinoma of the skin. It is a slow-growing cancer. It appears on areas of the body that are exposed to ultraviolet radiation, which is being exposed primarily to the sun. When the lesion appears and is diagnosed, the treatment available is what is called Mohs surgical procedure, which is a micrographic go around the lesion of the cancer and just curate out the cancer cells in a surgical suite done by an experienced surgeon." "We are trying to disrupt by delivering a known chemotherapeutic agent through these uniquely designed, cellulose-based microneedle arrays, which can penetrate the dermis and deliver a chemotherapeutic agent at the site of the lesion and kill the cancer cells, thereby eliminating the need of surgical intervention." "It is currently in clinical trial, but post-approval, it is ready to commercialize. We hope that the dermatologists who are also trained to do Mohs surgery before scheduling the surgery, which usually takes about six to eight weeks to schedule, can also invite the patients to, in an office setting, take our patch and have it placed over the site of the lesion for 30 minutes over three settings. So if a cancer is diagnosed today, you schedule Mohs surgery, which is considered the gold standard six to eight weeks out because that is the wait time. The average wait time in the United States is about six to eight weeks. You could provide an option to have these three sittings one week apart of 30 minutes of our patch and come back for an examination on week four or five. If the lesion has been cured and the skin has become clear, then there is no need for surgical intervention. If, for some reason, our treatment fails, the patient can go on and get more surgery done and eventually become cancer-free." #MedicusPharma #PatchCure #BasalCellPatch #PatchTherapy #BCC #BasalCellCarcinoma #SkinCancer #Biotech #Dermatology #ClinicalTrials #Phase2Trial #SkinCancerTreatment medicuspharma.com Download the transcript here
Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma, has developed a novel, non-invasive treatment for basal cell carcinoma, the most common form of skin cancer. This cost-effective transdermal Skinject patch delivers a chemotherapeutic agent applied in a clinician's office over three sessions to remove the lesion, potentially avoiding the need for Mohs surgery, the current standard of care. Medicus is incorporating AI and advanced imaging techniques in its clinical trials to improve diagnosis and monitoring of the treatment's effectiveness. Raza explains, "The gold standard to treat basal cell carcinoma of the skin is surgical intervention, generally speaking, all solid tumors to eliminate cancer if it is caught in the early stage. The treatment regimen is that you surgically take the malignant cells out. The same is true for basal cell carcinoma of the skin. It is a slow-growing cancer. It appears on areas of the body that are exposed to ultraviolet radiation, which is being exposed primarily to the sun. When the lesion appears and is diagnosed, the treatment available is what is called Mohs surgical procedure, which is a micrographic go around the lesion of the cancer and just curate out the cancer cells in a surgical suite done by an experienced surgeon." "We are trying to disrupt by delivering a known chemotherapeutic agent through these uniquely designed, cellulose-based microneedle arrays, which can penetrate the dermis and deliver a chemotherapeutic agent at the site of the lesion and kill the cancer cells, thereby eliminating the need of surgical intervention." "It is currently in clinical trial, but post-approval, it is ready to commercialize. We hope that the dermatologists who are also trained to do Mohs surgery before scheduling the surgery, which usually takes about six to eight weeks to schedule, can also invite the patients to, in an office setting, take our patch and have it placed over the site of the lesion for 30 minutes over three settings. So if a cancer is diagnosed today, you schedule Mohs surgery, which is considered the gold standard six to eight weeks out because that is the wait time. The average wait time in the United States is about six to eight weeks. You could provide an option to have these three sittings one week apart of 30 minutes of our patch and come back for an examination on week four or five. If the lesion has been cured and the skin has become clear, then there is no need for surgical intervention. If, for some reason, our treatment fails, the patient can go on and get more surgery done and eventually become cancer-free." #MedicusPharma #PatchCure #BasalCellPatch #PatchTherapy #BCC #BasalCellCarcinoma #SkinCancer #Biotech #Dermatology #ClinicalTrials #Phase2Trial #SkinCancerTreatment medicuspharma.com Listen to the podcast here
In this episode we welcome Dr. Candace (Candy) Tefertiller, an expert in spinal cord injury (SCI) rehabilitation, to explore the exciting potential of transcutaneous spinal stimulation (TSS) in augmenting motor recovery. Candy breaks down the mechanisms behind TSS, offers insights into the latest research, and shares the current and emerging clinical applications of this noninvasive technique. Together with host J.J. Mowder-Tinney, we dig into key considerations for therapists, including patient outcomes, and strategies for keeping a pulse on relevant research. Listen in to learn how TSS might be the next innovative intervention to augment SCI recovery. Interpret the evidence around the underlying mechanism associated with noninvasive spinal stimulation to facilitate sensory and motor recovery after SCI Apply evidence-based, practical strategies to actionably address motor recovery and activation after SCI, with a focus on enhancing functional outcomes in daily activities Solve patient case scenarios involving individuals with limited voluntary motor activation after SCI Timestamps: (00:00:00) Welcome (00:0049) Introduction to guest (00:03:05) Background and research focus (00:06:14) The impact of noninvasive spinal stimulation (00:10:04) Understanding transcutaneous spinal stimulation mechanisms (00:14:03) Comparing noninvasive and invasive spinal stimulation (00:15:54) Patient tolerance and individual variability in stimulation (00:18:01) Distinguishing between spinal and peripheral nerve stimulation (00:20:57) Current research status and future directions (00:25:38) Understanding noninvasive spinal stimulation (00:27:48) Research insights and case studies (00:30:55) Impact on spasticity and functional improvements (00:37:16) Key considerations for therapists (00:45:30) Real-world applications and patient engagement (00:48:51) The future of physical therapy and research Neuro Navigators is brought to you by Medbridge. If you'd like to earn continuing education credit for listening to this episode and access bonus takeaway handouts, log in to your Medbridge account and navigate to the course where you'll find accreditation details. If applicable, complete the post-course assessment and survey to be eligible for credit. The takeaway handout on Medbridge gives you the key points mentioned in this episode, along with additional resources you can implement into your practice right away. To hear more episodes of Neuro Navigators, visit https://www.medbridge.com/neuro-navigators If you'd like to subscribe to Medbridge, visit https://www.medbridge.com/pricing/
Show Notes 27 December 2024Story 1: Google 'Willow' quantum chip has solved a problem the best supercomputer would have taken a quadrillion times the age of the universe to crackSource: LiveScience.com Story by Afifi-SabetLink: https://www.livescience.com/technology/computing/google-willow-quantum-computing-chip-solved-a-problem-the-best-supercomputer-taken-a-quadrillion-times-age-of-the-universe-to-crackSee also: https://arxiv.org/abs/2408.13687Story 2: IBM Study: “Vehicles Believed to be Software-Defined and AI-Powered by 2035”Source: AutoTechNews Press RoomLink: https://autotech.news/ibm-study-vehicles-believed-to-be-software-defined-and-ai-powered-by-2035/See also: https://www.ibm.com/thought-leadership/institute-business-value/en-us/report/automotive-2035Story 3: Mercedes is working on "solar paint" that could drastically reduce the need for charging - Enough juice for 12,000 km per year in sunny areasSource: TechSpot.com Story by Zo AhmedLink: https://www.techspot.com/news/105884-mercedes-working-solar-paint-could-eliminate-need-charging.html Story 4: Noninvasive imaging method can penetrate deeper into living tissue - Using high-powered lasers, this new method could help biologists study the body's immune responses and develop new medicinesSource: MIT News Story by Adam ZeweLink: https://news.mit.edu/2024/noninvasive-imaging-method-can-penetrate-deeper-living-tissue-1211For more info, interviews, reviews, news, radio, podcasts, video, and more, check out ComputerAmerica.com!
Noninvasive cardiac testing (1:30), SGLT-2 inhibitors (5:30), opioid prescribing (8:10), children with hypertension (10:20), anemia in infants and children (12:00), premenstrual disorders (15:20), and holiday ICD-10 codes (18:00).
“Your skin is the first place you see your overall health and wellness,” says Teo Soleymani, M.D. Soleymani, double board-certified and fellowship trained Mohs micrographic, dermatologic and facial plastic and reconstructive surgeon, joins us to discuss everything you need to know about skin health–from preventing skin cancer and proper sun protection to improving skin appearance, plus: - Soleymani's training & focus (~2:07) - Soleymani's approach to skin care (~3:40) - Genetics & skin health (~5:20) - The truth about sunscreen (~10:28) - Actionable tips for those with a family history of skin cancer (~12:23) - UV index & sun exposure (~15:03) - Lifestyle impacts of skin health (~19:42) - Inflammation and skin health (~20:30) - Seed oils & your skin (~23:55) - Gluten, dairy, & sugar (~32:00) - Treating skin damage (~36:15) - Lasers & resurfacing devices (~39:10) - Red light therapy (~43:48) - Noninvasive procedures (~45:45) - Wrinkles (~49:45) - Underrated & overrated treatments (~53:10) - Cutting edge research (~57:10) Referenced in the episode: - Follow Soleymani on Instagram (teosoleymanimd) - Visit his clinic (https://www.californiadermatology.com/) - Learn about sun powder (https://sunpowder.co/) - Research on nicotinamide for skin cancer prevention (DOI: 10.1056/NEJMoa1506197) - Research on nonablative fractional laser treatment (DOI: 10.1097/DSS.0000000000003672) We hope you enjoy this episode, and feel free to watch the full video on YouTube! Whether it's an article or podcast, we want to know what we can do to help here at mindbodygreen. Let us know at: podcast@mindbodygreen.com. Learn more about your ad choices. Visit megaphone.fm/adchoices
Commentary by Dr. Jian'an Wang.
Natalie Schroeder joins us today for the second part of our two-part series on BTL devices. In Part 1 last week, we discussed the two new devices we recently launched at the Integrative Health and Hormone Clinic, the Emsella Chair, to strengthen the pelvic floor and assist with incontinence and sexual function, and the Emsculpt Neo, to help reduce body and visceral fat and gain muscle. In this episode, we dive into the non-surgical technology options designed to help improve the body and face without injections or surgery, including Exion, Emface, radio frequency micro-needling, the body-hand piece, Emfem, and Emtone for cellulite. If you have not yet done so, please listen to Part 1 before joining us for Part 2. The benefits of radio frequency treatments and mechanical ultrasound: Increases collagen Improves elastin Contributes to elasticity Helps to remodel scars Natalie Schroeder's Bio: Natalie Schroeder is a registered nurse who has been working in the health and wellness industry for over 25 years. She has managed a dental practice, worked as an RN in the hospital at the bedside and in critical care, and eventually transitioned to a medical spa where she worked as an injector. She also coaches fitness classes and is passionate about the health and wellness of her four children and being the best version of herself. In this episode: Natalie introduces BTL's non-invasive devices for facial treatments Natalie explains how the Exion Tower and its four different attachments work How the face handpiece addresses hyperpigmentation, laxity, lines, and wrinkles How the body handpiece targets skin laxity and fat reduction, with specific applications for men and women The benefits of RF micro-needling for scar remodeling, stretch marks, and skin laxity How the Emfem device for vaginal rejuvenation tackles laxity and blood flow How the Emtone device breaks up cellulite bands and smooths the skin Our upcoming event on November 12, where Natalie will present and provide demos of the various BTL devices Links and Resources: Use code Drgray20 to get 20% off Perfect Aminos Follow Your Longevity Blueprint On Instagram| Facebook| Twitter| YouTube | LinkedIn Get your copy of the Your Longevity Blueprint book and claim your bonuses here Find Dr. Stephanie Gray and Your Longevity Blueprint online Follow Dr. Stephanie Gray on Facebook| Instagram| Youtube | Twitter | LinkedIn Integrative Health and Hormone Clinic Podcast production by Team Podcast Guest Social Media Links: Natalie on Instagram(Btl_natalie) BTL Aesthetics on Instagram(btlaesthetics) Relative Links for This Show: BTL Aesthetics
Hear the latest groundbreaking news in Alzheimer's research. Sinaptica, a member of StartUp Health's Alzheimer's Moonshot Community, has announced significant results from its Phase 2 clinical trial testing the company's noninvasive, personalized, precise neuromodulation designed to stop the progression of Alzheimer's disease. Ken Mariash, CEO of Sinaptica, joined us in the StartUp Health Studio to break it all down for us. As you'll hear, the interview took place prior to the release of this data, which became public on October 31. In this exclusive interview, you'll learn: Details on Sinaptica's Phase 2 trial results show significant promise in slowing Alzheimer's progression The science behind Sinaptica's technology How personalized neuromodulation is revolutionizing brain health The potential for proactive brain strengthening and repair The impact on patients' daily lives The future of Alzheimer's treatment This episode is a must-listen for anyone interested in Alzheimer's research, neuroscience, and the power of innovation to transform lives. Are you ready to tell your story? Members of our Health Moonshot Communities are leading startups with breakthrough technology-driven solutions for the world's biggest health challenges. Exposure in StartUp Health Media to our global audience of investors and partners – including our podcast, newsletters, magazine, and YouTube channel – is a benefit of StartUp Health's PRO Membership. To schedule a call and see if you qualify to join and increase brand awareness through our multi-media storytelling efforts, submit our three-minute application. If you're mission-driven, collaborative, and ready to contribute as much as you gain, you might be the perfect fit. Learn more and apply today. Want more content like this? Sign up for StartUp Health Insider™ to get funding insights, news, and special updates delivered to your inbox.
Prapela is a medical device company focused on improving newborn health. Their primary product is a specially designed mattress that uses gentle vibrations to regulate infant breathing, particularly for babies experiencing apnea of prematurity and neonatal opioid withdrawal syndrome.CEO & co-founder, John Konsin, joins this episode to share how many newborns, especially premature babies, experience breathing irregularities, including apnea and oxygen desaturation. Prapela's innovative mattress offers a non-invasive solution than can reduce the need for additional interventions while lowering costs for hospitals.Prapela's market potential is significant, as it addresses a common and serious issue affecting newborn infants. Building on decades of research and recent exciting clinical evidence, the Prapela journey is definitely one to track, be sure to tune in so you can be informed and inspired.
We recently launched two new devices at the Integrative Health and Hormone Clinic. So we now have the Emsella Chair for strengthening the pelvic floor and assisting with incontinence and sexual function, and the Emsculpt Neo to help reduce body and visceral fat and gain muscle. Natalie Schroeder joins us for a two-part series to unravel these exciting new technologies. In Part 1 today, Nurse Natalie discusses BTL Aesthetics, the Emsella Chair, and the Emsculpt Neo. In Part 2, she will break down other BTL devices that can benefit the face and body. What the Emsella chair can treat: Pelvic floor dysfunction Urinary incontinence Intimate wellness What the Emsculpt Neo Does: Builds muscle mass Melts body fat Reduces visceral fat Natalie Schroeder's Bio: Natalie Schroeder is a registered nurse who has been working in the health and wellness industry for over 25 years. She has managed a dental practice, worked as an RN in the hospital at the bedside and in critical care, and eventually transitioned to a medical spa where she worked as an injector. She also coaches fitness classes and is passionate about the health and wellness of her four children and being the best version of herself. In this episode: The unique aspects that make BTL a global leader in medical device manufacturing Natalie gives an overview of the Emsella Chair The benefits of using the Emsella Chair Why pelvic floor issues must be treated early Natalie introduces the Emsculpt Neo How the dual energy technology of the Emsculpt Neo achieves 100% muscle contraction and significant calorie burn The benefits of the Core Floor Therapy program Who are the ideal candidates for the Emsculpt Neo? Links and Resources: Use code Immune Support to get 10% off Immune Support Use code Drgray20 to get 20% off Perfect Aminos Follow Your Longevity Blueprint On Instagram | Facebook | Twitter | YouTube | LinkedIn Get your copy of the Your Longevity Blueprint book and claim your bonuses here Find Dr. Stephanie Gray and Your Longevity Blueprint online Follow Dr. Stephanie Gray on Facebook | Instagram | Youtube | Twitter | LinkedIn Integrative Health and Hormone Clinic Podcast production by Team Podcast Guest Social Media Links: Natalie on Instagram (Btl_natalie) BTL Aesthetics on Instagram (btlaesthetics) Relative Links for This Show: BTL Aesthetics
In recognition of Breast Cancer Awareness Month, Dr. Greg Czarnota, a senior scientist and radiation oncologist at Sunnybrook Research Institute in Toronto, discusses his innovative research using focused ultrasound in breast cancer treatment. Dr. Czarnota shares promising results from his phase I clinical trial using focused ultrasound-stimulated microbubbles to enhance radiotherapy in patients with advanced breast cancers. Key points from the conversation include: The origins of Dr. Czarnota's interest in focused ultrasound and its application in enhancing radiotherapy. He shares details of the upcoming phase II clinical trials that will be enrolling patients with inoperable breast cancer. Technical advances with the Arrayus focused ultrasound device could treat larger and more complex tumors. Dr. Czarnota has also developed ultrasound imaging methods to detect cell death. SHOW TRANSCRIPT ---------------------------- QUESTIONS? Email podcast@fusfoundation.org if you have a question or comment about the show, or if you would you like to connect about future guest appearances. Email info@fusfoundation.org if you have questions about focused ultrasound or the Foundation. FUSF SOCIAL MEDIA LinkedIn X Facebook Instagram TikTok YouTube FUSF WEBSITE https://www.fusfoundation.org SIGN UP FOR OUR FREE NEWSLETTER https://www.fusfoundation.org/newsletter-signup/ READ THE LATEST NEWSLETTER https://www.fusfoundation.org/the-foundation/news-media/newsletter/ DOWNLOAD "THE TUMOR" BY JOHN GRISHAM (FREE E-BOOK) https://www.fusfoundation.org/read-the-tumor-by-john-grisham/
Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on impact of the noninvasive diagnostic algorithm on clinical presentation and prognosis in cardiac amyloidosis.
View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this quarterly podcast summary (QPS) episode, Peter summarizes his biggest takeaways from the last three months of guest interviews on the podcast. Peter shares key insights from each episode, covering diverse topics such as liver health with Julia Wattacheril, heart rate variability with Joel Jamieson, artificial intelligence with Zak Kohane, klotho for brain health with Dena Dubal, and lactate and lactate metabolism with George Brooks. Additionally, Peter shares any personal behavioral adjustments or modifications to his patient care practices that have arisen from these engaging discussions. If you're not a subscriber and are listening on a podcast player, you'll only be able to hear a preview of the AMA. If you're a subscriber, you can now listen to this full episode on your private RSS feed or our website at the episode #319 show notes page. If you are not a subscriber, you can learn more about the subscriber benefits here. We discuss: Overview of topics, and the positive feedback on the quarterly podcast summary format [2:00]; Julia Wattacheril episode: liver health and disease [4:00]; Noninvasive methods to diagnose liver conditions, and how to manage and improve liver health [16:00]; Joel Jamieson episode: heart rate variability (HRV) for training and health [27:15]; Practical tools for measuring HRV and how it informs training and recovery decisions [37:00]; Zak Kohane episode: artificial intelligence and medicine [47:15]; The current role of AI in medicine and how it could revolutionize medicine in the future [53:45]; The limitations and concerns pertaining to AI [1:00:15]; Dena Dubal episode: the potential benefits of klotho for brain health [1:05:00]; Animal studies on klotho and brain health [1:11:00]; Genetics-based variations in klotho levels in humans and their impact on cognition, disease risk, and longevity [1:14:15]; Testing klotho levels, the significance of the KL-VS variant, the role of exercise in increasing klotho, and more [1:17:30]; The potential of klotho as a treatment for cognitive decline and Alzheimer's disease [1:23:15]; George Brooks episode: a new paradigm to think about lactate and lactate metabolism [1:27:45]; The potential for lactate infusions to aid in brain recovery following a head injury [1:34:00]; The relationship between lactate and cancer, and the impact of exercise on lactate levels and cancer risk [1:36:30]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube
Stay ahead with the newest cardiology research findings that could change your clinical practice! STUDY #1: First up, we explore new data on edoxaban dosage for older patients with atrial fibrillation. If we could give older patients a lower dose of edoxaban to reduce the risk of bleeding, will they still benefit from a lower risk for stroke? Zimerman, A, Braunwald, E, Steffel, J, et al. 2024. Dose reduction of edoxaban in patients 80 years and older with atrial fibrillation: Post hoc analysis of the ENGAGE AF-TIMI 48 randomized clinical trial. JAMA Cardiol. Published online. (https://doi.org/10.1001/jamacardio.2024.1793) STUDY #2: Next, we delve into the nuanced world of invasive versus noninvasive treatment of non-ST-segment elevation myocardial infarction (NSTEMI). You'll find out if mortality rates go up when we use a less invasive approach. Kunadian, V, Mossop, H, Shields, C, et al. 2024. Invasive treatment strategy for older patients with myocardial infarction. N Engl J Med. Published online. (https://doi.org/10.1056/NEJMoa2407791) STUDY #3: Lastly, we break down the latest findings on chelation therapy in patients with stable coronary artery disease and diabetes. Tune it to see whether the latest data challenges your perspective on the efficacy of EDTA in reducing cardiovascular risks. Lamas, GA, Anstrom, KJ, Navas-Acien, A, et al. 2024. Edetate disodium-based chelation for patients with a previous myocardial infarction and diabetes: TACT2 randomized clinical trial. JAMA. Published online. (https://doi.org/10.1001/jama.2024.11463) Join us to uncover these critical insights, discussions, and more. Let's turn data into actionable wisdom and elevate your cardiology practice. Learn more with Medmastery's courses: ECG Mastery Program (34 CME) Get a Basic or Pro account, or, get a Trial account. Show notes: Visit us at https://www.medmastery.com/podcasts/cardiology-podcast.
Noninvasive hair loss treatments are changing the way we approach hair restoration, offering new hope for those looking to maintain and enhance their natural hair without the need for surgery. With millions affected by hair loss, these cutting-edge techniques, such as TED (transepidermal delivery) and PRP, provide effective, personalized solutions that focus on early intervention and long-term results. In this podcast, I'm joined by Dr. Alan Bauman, a hair transplant surgeon based in Boca Raton, Florida. We'll explore how these innovative treatments are reshaping hair restoration, the importance of addressing hair loss early, and the benefits of tailored treatment plans. Whether you're dealing with hair loss or simply curious about the latest advancements in hair restoration, this conversation is packed with valuable insights and practical advice to help you take control of your hair health. Connect with me across Social: Instagram: https://www.instagram.com/drhannahkopelman/ TikTok: https://www.tiktok.com/@drhankopelman Twitter: https://twitter.com/drhankopelman Pinterest: https://www.pinterest.com/drhankopelman/ Personal Site: https://www.hannahkopelman.com The content of this podcast is for entertainment and educational purposes only. This content is not meant to be a substitute for medical advice or treatment for any medical condition.
Dr. Imad Khan is an assistant professor in the Division of NeuroCritical Care at the University of Rochester. His research focuses on monitoring cerebral perfusion and pathophysiology in patients with […]
Dr. Raza Bokhari, Executive Chairman and CEO of Medicus Pharma joined Steve Darling from Proactive to announce the submission of a comprehensive and updated Phase 2 Investigational New Drug clinical protocol to the United States Food and Drug Administration (FDA). This protocol aims to non-invasively treat basal cell carcinoma of the skin using micro-needle arrays containing doxorubicin, developed by Medicus Pharma's wholly owned portfolio company, Skinject, Inc. The submission features significant updates to the clinical protocol, including enhancements to the supporting Chemistry, Manufacturing, and Controls (CMC), along with detailed stability and sterility information. Furthermore, it addresses the clinical non-hold comments previously received from the FDA, ensuring a robust and thorough response to regulatory feedback. Dr. Bokhari shared with Proactive that the revised Phase 2 clinical protocol incorporates innovative elements such as artificial intelligence and confocal microscopy as supplementary endpoints at one of the clinical sites. These advanced technologies are expected to provide deeper insights and improved accuracy in the clinical outcomes. Medicus Pharma believes that this updated protocol is well-positioned to receive FDA approval, paving the way for the commencement of participant randomization potentially before the end of this quarter. This milestone underscores the company's commitment to advancing innovative treatments for skin cancer and improving patient outcomes through cutting-edge technology and rigorous clinical research. #proactiveinvestors #medicuspharmaltd #tsxv #mdcx #fda #clinicaltrials #RazaBokhari, #BasalCellCarcinoma, #CancerTreatment, #NonInvasive, #FDA, #ClinicalTrials, #AIinHealthcare, #ConfocalMicroscopy, #BiotechFunding, #Chemotherapeutics, #SkinCancer, #DrugDevelopment, #HealthcareInnovation, #MedicalResearch, #PatientCare, #ArtificialIntelligence, #MedicalAdvancements, #Pharmaceuticals, #TorontoStockExchange, #HealthcareTech#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
Episode 172: NAFLD and ObesityFuture Dr. Nguyen explains the pathophysiology of non-alcoholic fatty liver disease and how it relates to obesity. Dr. Arreaza gives information about screening and diagnosis of NAFLD. Written by Ryan Nguyen, MS4, Ross University School of Medicine. Comments by Hector Arreaza, MD.You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Introduction/PathophysiologyNonalcoholic fatty liver disease (NAFLD) refers to the buildup of excess fat in liver cells, occurring without the influence of alcohol or drugs. Nonalcoholic steatohepatitis (NASH) represents a more severe form of NAFLD, characterized by inflammation and liver cell injury due to fat accumulation. If left untreated, NASH can progress to liver fibrosis or cirrhosis. Typically, NAFLD/NASH is diagnosed after other liver conditions are ruled out, making it a diagnosis of exclusion.NAFLD -> NASH -> Cirrhosis -> Liver failure. Another term for NAFLD is metabolic dysfunction-associated steatotic liver disease. Fatty liver disease is identified when more than 5% of liver weight consists of fat, whereas, NASH is diagnosed when this fat accumulation is accompanied by inflammation and liver cell injury, sometimes leading to fibrosis. Understanding these distinctions is crucial in recognizing and managing the spectrum of liver conditions associated with obesity and metabolic syndrome.BMI serves as a tool to gauge body fat levels: individuals are categorized as normal weight if their BMI falls between 18.5 and 24.9, overweight if it ranges from 25 to 29.9. Class I obesity is diagnosed with a BMI of 30 to 34.9, class II obesity between 35 and 39.9, and class III obesity when BMI exceeds 40.Obesity puts you at risk of NAFLD, but you can also see NAFLD in non-obese patients, but the prevalence is very low, about 5%. What did you learn about the demographics of NAFLD?NAFLD is most widespread in regions like South Asia, the Middle East, Mexico, Central and South America, with prevalence rates exceeding 30%. In the United States, prevalence varies with approximately 23-27%, notably higher among Asians at 30%, followed by Hispanic individuals at 21%, White individuals at 12.5%, and Black individuals at 11.6%. Across all racial groups, obesity plays a significant role, affecting more than two-thirds of individuals diagnosed with NAFLD. Understanding these demographics underscores the global impact of obesity on NAFLD prevalence.Diagnosis: Screening/Labs/Imaging/ToolsThe American Association for the Study of Liver Diseases does not recommend screening for NAFLD, but if it is discovered an appropriate workup is warranted. AST/ALT RatioLiver health can be assessed by a series of tests aimed at assessing fat accumulation, inflammation, and fibrosis. Initial screening often includes laboratory tests such as measuring the ratio between aspartate transaminase (AST) and alanine transaminase (ALT), where a ratio less than 1 may suggest possible NAFLD, although it is not diagnostic on its own. Normally, AST is slightly more elevated than ALT. So, if the AST/ALT ratio is lower, then means that ALT is higher than AST. FibroSure®.Additionally, you can measure indirect markers of fibrosis with tests such as FibroSure or FibroTest blood tests that combine several biomarkers including age, sex, gamma-glutamyl-transferase (GGT), total bilirubin, alpha-2-macroglobulin, apolipoprotein A1, haptoglobin, and ALT to provide insights into liver health.Some people may be more familiar with FibroSure before Hepatitis C treatment. You can get a fibrosis score (F0-F4), and it is considered significant fibrosis if the score is > or equal to F2. Imaging plays a crucial role in diagnosing NAFLD without the need for invasive procedures like liver biopsy. Vibration-controlled transient elastography (Fibroscan) uses ultrasound to measure liver stiffness, indicating potential fibrosis and inflammation. While noninvasive and portable, it focuses solely on liver ultrasound and may not be universally accessible. MRI with proton density fat fraction (MRI-PDFF) offers a comprehensive assessment of liver fat content, commonly used in clinical and research settings for NAFLD and NASH evaluation.For evaluating hepatic fibrosis in patients with suspected NAFLD, tools like the Fibrosis-4 Index (FIB-4) incorporate age, AST, ALT, and platelet count to estimate the likelihood of liver disease progression. These screening methods collectively aid in diagnosing and monitoring NAFLD, particularly in individuals at risk due to factors like prediabetes, type 2 diabetes, obesity, and abnormal liver enzyme ratios. With the FIB-4 you can get a faster answer than FibroSure because you only need 4 elements: Age, platelet count, AST and ALT. Cirrhosis is less likely if FIB-4 is 3.25. Understanding these diagnostic approaches is essential for early detection and management of NAFLD in clinical practice.Some researchers are invested in diagnosis and treating NAFLD while others recommend against labeling patients with NAFLD. A 2018 Lancet article concluded that the risks of over-diagnosing and overtreating NAFLD exceed the benefits of screening or periodic imaging because of “the low hepatic mortality, high false-positive rate of ultrasonography, selection bias of current studies, and lack of viable treatment.” However, patients who suffer from metabolic syndrome should be counseled about dietary modification and physical activity regardless of their liver condition. NAFLD and obesityFatty liver disease is often caused by multiple insults towards either genetically or environmentally predisposed individuals. Family history of NAFLD and having specific genetic variants are important risk factors for NAFLD. Those with prior health conditions can have increased susceptibility to NAFLD including T2DM leading to insulin resistance, metabolic syndrome, sleep apnea, hepatitis C, and cardiovascular or chronic kidney disease. A sedentary lifestyle and unhealthy nutrition (especially high intake of processed carbohydrates) cause an increase in free fatty acids leading to hepatic fat deposition → ballooning of hepatocytes → leading to hepatocyte injury/death → inflammation with fibroblast recruitment → end result of fibrosis/cirrhosis. Just a quick reminder, NAFLD is defined as fatty liver with >5% hepatic fat and NASH is defined as fatty liver with >5% hepatic fat with inflammation, hepatocyte injury, with or without fibrosis that we can determine through imaging. A leading concern for the development of NAFLD is the consumption of high fructose corn syrup. High fructose corn syrup (HFCS), commonly found in candy, processed sweets, soda, fruit juices, and other processed foods, is linked to non-alcoholic fatty liver disease (NAFLD). Unlike natural whole fruits, which contain fiber and are generally healthier due to their slower absorption, HFCS lacks fiber and is quickly absorbed, leading to rapid transport to the liver. This process contributes to NAFLD by increasing the hepatic synthesis of lipids and interfering with insulin signaling. To avoid HFCS, individuals are encouraged to consume whole fruits rather than fruit juices and adopt diets rich in whole grains, lean meats, plant-based proteins, fruits, and vegetables, such as the Mediterranean or DASH diets, which are less likely to promote NAFLD, especially in those with healthy body weight.NAFLD treatment.Avoiding alcohol seems very obvious, but we need to mention it. Avoiding heavy alcohol consumption is recommended and complete abstinence is suggested.Weight loss is crucial; even a modest reduction of 3–5% in body weight can alleviate hepatic steatosis, with greater improvements typically seen with 7–10% weight loss, particularly beneficial for addressing histopathological features of NASH, such as fibrosis. We must focus on tailored medical nutrition therapy and regular physical activity. A strategic meal plan is essential, emphasizing achieving a healthy body weight while limiting trans fats and ultra-processed carbohydrates. Options like the Mediterranean diet, which balances lean proteins and restricts processed carbohydrates have shown promise. Dynamic aerobic and resistance exercises play a significant role in managing NAFLD. They help maintain a healthy weight and enhance peripheral insulin sensitivity, reduce circulating free fatty acids and glucose levels, and boost intrahepatic fatty acid oxidation while curbing fatty acid synthesis. These benefits contribute to mitigating liver damage associated with NAFLD, offering therapeutic advantages beyond mere weight reduction.Exercise may not be a great tool for weight loss, but it is a great tool for weight maintenance, liver health, and overall health as well. “Most patients with NAFLD die from vascular causes, but NAFLD puts patients at increased risk of cardiovascular death”. Medications for NAFLD.Regarding pharmacotherapy, while no medications are currently FDA-approved specifically for NAFLD treatment, some options show promise in clinical settings. Vitamin E supplementation at 800 IU (international units) daily has demonstrated biochemical and histological improvements in NASH cases without diabetes or cirrhosis, though long-term use may elevate prostate cancer risks. It is important to make a shared decision with the patient before starting Vitamin E supplementation. Medications like pioglitazone can reduce liver fat and improve NASH, even as they may increase body weight. But our favorite, GLP-1 receptor agonists, such as liraglutide and semaglutide, also show potential in reducing liver fat and improving NASH symptoms, and this is an emerging therapeutic option for managing this condition.If you decide to treat, then you should monitor as part of the treatment. An aminotransferase check is recommended 6 months after starting a weight loss program. If levels do not improve or do not return to normal after 5-7% of weight loss, another cause of elevated transaminases needs to be investigated.You also need to monitor fibrosis in patients with >F2. If fibrosis has been proven by liver biopsy, you can order FibroSure every 3-4 years. Having a fatty liver may be a red flag that your patient has a metabolic problem. If you discover it, start interventions that would benefit not only the liver but the whole metabolic profile of your patient. The Obesity Medicine Association (OMA) issued a Clinical Practice Statement (CPS) regarding NAFLD and obesity stating that patients with obesity are at increased risk for NAFLD and NASH. It recommends that clinicians strive to understand the etiology, diagnosis, and optimal treatment of NAFLD with a goal to prevent NASH in their patients.Regular exercise, even walking 30 minutes a day can show many benefits in curbing fatty accumulation in the liver. Having a proper diet with avoidance of high fructose corn syrup can overall help in reducing NAFLD/NASH. _____________________Conclusion: Now we conclude episode number 172, “NAFLD and Obesity.” Future Dr. Nguyen explained that NAFLD and obesity are closely related and NAFLD can lead to NASH and cirrhosis in some patients. Dr. Arreaza explained that screening may not be recommended by some medical societies, but others are in favor of screening and treating this disease. However, most people agree that NAFLD is a sign of metabolic disease and a good reason to talk about healthy eating and physical activity with our patients. There are no FDA-approved medications to treat NAFLD, but some evidence suggests that Vitamin E can improve it and GLP-1 receptor agonists are a promising option. This week we thank Hector Arreaza and Ryan Nguyen. Audio editing by Adrianne Silva.Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________References:Karjoo S, Auriemma A, Fraker T, Edward H. Nonalcoholic fatty liver disease and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022. https://doi.org/10.1016/j.obpill.2022.100027.Curry M, Afdhal N. Noninvasive assessment of hepatic fibrosis: Overview of serologic tests and imaging examinations. https://www.uptodate.com/contents/noninvasive-assessment-of-hepatic-fibrosis-overview-of-serologic-tests-and-imaging-examinationsRoyalty-free music used for this episode: Cool Groove (Alt-Mix) by Videvo, downloaded on Nov 06, 2023, from https://www.videvo.net
Commentary by Dr. Candice Silversides
What's the best way to pre-oxygenate our patients prior to intubation? The evidence for this question has been mixed for some time. Dr Jarvis discusses the PREOXI Trial that directly compares preoxygenation with non-invasive ventilation compared to face mask, to see which provides the best protection against peri-intubation hypoxia. This is an important trial that sheds light on a key component of our bundle of care to make intubation safer.Citations:Gibbs KW, Semler MW, Driver BE, Seitz KP, Stempek SB, Taylor C, Resnick-Ault D, White HD, Gandotra S, Doerschug KC, et al.: Noninvasive Ventilation for Preoxygenation during Emergency Intubation. N Engl J Med. (2024)Jarvis JL, Gonzales J, Johns D, Sager L: Implementation of a Clinical Bundle to Reduce Out-of-Hospital Peri-intubation Hypoxia. Annals of Emergency Medicine. 2018;72:272–9.Groombridge C, et al: A prospective, randomised trial of pre-oxygenation strategies available in the pre-hospital environment. Anaesthesia. 2017;72:580–4.Groombridge C, et al: Assessment of Common Preoxygenation Strategies Outside of the Operating Room Environment. Acad Emerg Med. 2016;March;23(3):342–6.Baillard C, et al: Noninvasive ventilation improves preoxygenation before intubation of hypoxic patients. Am J Respir Crit Care Med. 2006;July 15;174(2):171–7.Ramkumar V, et al: Preoxygenation with 20-degree head-up tilt provides longer duration of non-hypoxic apnea than conventional preoxygenation in non-obese healthy adults. J Anesth. 2011;25:189–94.Pourmand A, et al: Pre-oxygenation: Implications in emergency airway management. American Journal of Emergency Medicine. doi: 10.1016/j.ajem.2017.06.006Solis A, Baillard C: Effectiveness of preoxygenation using the head-up position and noninvasive ventilation to reduce hypoxaemia during intubation. Ann Fr Anesth Reanim. 2008;June;27(6):490–4.April MD, Arana A, Reynolds JC, Carlson JN, Davis WT, Schauer SG, Oliver JJ, Summers SM, Long B, Walls RM, et al.: Peri-intubation cardiac arrest in the Emergency Department: A National Emergency Airway Registry (NEAR) study. Resuscitation. 2021;May;162:403–11.Trent SA, Driver BE, Prekker ME, Barnes CR, Brewer JM, Doerschug KC, Gaillard JP, Gibbs KW, Ghamande S, Hughes CG, et al.: Defining Successful Intubation on the First AttemptUsing Both Laryngoscope and Endotracheal Tube Insertions: A Secondary Analysis of Clinical Trial Data. Annals of Emergency Medicine. 2023;82(4):S0196064423002135.Pavlov I, Medrano S, Weingart S: Apneic oxygenation reduces the incidence of hypoxemia during emergency intubation: A systematic review and meta-analysis. AJEM. 2017;35(8):1184–9.
Ever wonder how all your favorite celebrities seem to have perfect, dewy, glass skin on the red carpet? The answer is simple: Iván Pol. This week on Lipstick on the Rim, he's sharing all his secrets. The former makeup artist turned facialist talks us through his iconic Beauty Sandwich Facial, how you can achieve results at home, and even shares some of his best-kept makeup secrets for achieving a snatched, defined, and lifted look (hint: it involves using your eyebrow gel on your cheeks—you'll have to listen to find out how that works)!Mentioned in this episode:The Beauty Sandwich SS01 SECRET SAUCEThe Beauty Sandwich SS02 SNATCHING SAUCEThe Beauty Sandwich AMUSE BOUCHEFurtuna Skin Micellar Cleansing EssenceChanel Anti-Pollution Micellar Cleansing WaterHallstein Artesian Natural Alkaline Still WaterDr. Lara Devgan Hyaluronic SerumChanel SUBLIMAGE L'EXTRAIT DE NUITChanel N°1 DE CHANEL LIP AND CHEEK BALM in Vital BeigeDr. Lara Devgan Platinum Lip Plump SPF 30Dr. Lara Devgan Extreme Lengthening MascaraAnastasia Beverly Hills Brow Freeze® GelSponsors:Shop Macy's ‘Lowest Price of the Season Sale' online at Macys.com or in-store from June 19th to the 23rd.Go to tryarmra.com/LIPSTICK or enter LIPSTICK to get 15% off your first order.Find your new uniform online at jennikayne.com. Our listeners get 15% off your first order when you use code LIPSTICK15 at checkout. Go to signos.com and get up to 20% off select plans with code LIPSTICK.Right now, you can get an exclusive 20% off your first order at thrivecausemetics.com/LIPSTICK. Please note that this episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct or indirect financial interest in products or services referred to in this episode.Produced by Dear Media.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
CME credits: 1.00 Valid until: 13-06-2025 Claim your CME credit at https://reachmd.com/programs/cme/noninvasive-tests-for-clinically-significant-fibrosis-thats-the-hepatologists-job-right/26257/ This series of bite-sized episodes will provide important information on MASLD and MASH in patients with type 2 diabetes. Drs. Naim Alkhouri and Robert Eckel and physician assistant Tessa Janovsky discuss best practices for screening, diagnosis, treatment, and management of MASH/MASLD.
Bladder symptoms are extremely common in individuals with MS. These symptoms include urinary frequency, urgency, incontinence or difficulty voiding or both. Voiding dysfunction (VD), a common neurogenic lower urinary tract symptom in individuals with multiple sclerosis (MS), often leads to urinary retention. The current primary management for MS patients with VD involves catheterization. Our team has explored the safety and therapeutic effects of a multi focal transcranial magnetic stimulator, a noninvasive, portable neuromodulator capable of simultaneously stimulating or inhibiting multiple brian regions and modulating the strength of their functional connections called Transcranial Rotating Permanent Magnet Stimulator (TRPMS). In this study, MS women with VD underwent functional magnetic resonance imaging concurrently with a urodynamic study (fMRI/UDS) before and after ten 40-minute TRPMS sessions. Baseline fMRI/UDS scans identified regions of interest (ROIs) associated with voiding initiation, guiding microstimulator placement. Post-treatment, patients exhibited increased activation in these ROIs, a significant decrease in % post-void residual/bladder capacity (%PVR/BC), and reported improved bladder symptoms including more effective bladder emptying. Individuals seeking further information visit khavariresearch.com, reach out via email at msbladder@houstonmethodist.org, or locate details on clinicaltrials.gov where it is registered.
Reliability of COVID-19 tests unreliable; Insulin pump app updated following battery issue; Noninvasive colorectal cancer test gets FDA approval; Self-collection HPV screening option; National Drug Threat Assessment highlights illicit drugs currently endangering the US.
Alicia Algeciras-Schimnich, Ph.D., discusses how Mayo Clinic Laboratories' new noninvasive blood test for Alzheimer's disease identifies the p-tau217 biomarker, which is associated with the accumulation of amyloid beta in the brain. Positive test results can facilitate access to disease-modifying therapies. (00:32):Dr. Algeciras, could you just provide a little bit of background on your role at Mayo Clinic?(01:45):So before we get into the test itself, can you just explain a little bit about the disease state and especially some of the recent changes? (07:39) So can you explain a little bit more about what the results that our clients will receive look like? (10:30) Can you just give a quick overview of how our test is unique compared to those on the market? (12:24) What patients should have this testing performed, Dr. Algeciras and if you have any tips on which patients should not, please include that as well? (14:42) Let's talk now about how those results are used in patient care. (16:31) One more question, just summarize for our listeners what you're most excited about with this new test.
Dr. Kamangar and Dr. Sarah Arron disucss non-invasive skin imaging which allows dermatologists to see beneath the surface of the skin without the need for biopsies. They also chat about the VIO system, the first of its kind technology. To learn more, check out these articles and websites: Enspectra Health Announces US FDA Clearance of VIO™ System, First of Its Kind Technology to Visualize Skin Cellular Structures in Real-Time Enspectra Health Website Research Techniques Made Simple: Emerging Imaging Technologies for Noninvasive Optical Biopsy of Human Skin UCSF Rosenman Institute Fogarty Innovation
Cerebral palsy, spinal cord injury, and other neurological conditions can impact how information travels from your brain to other parts of your body. SpineX, a startup company in our 2023 Remarkable US Accelerator Program, develops noninvasive solutions that use painless electrical stimulation to change the nervous system's activity to improve function and enhance quality of life. In this episode, you'll hear more about the company and its innovative Spinal Cord Innovation in Pediatrics (SCiP™) device and Spinal Cord Neuromodulation (SCONE™) device from Kara Allanach, SpineX's Director of Product. In the second part of our interview, you'll meet Jessica, Van, and Annika Oldham. They discuss Annika's cerebral palsy, their experiences with the SCiP™ device as part of two clinical research studies, and the improvements they've seen in Annika's mobility. Please note: SCiP™ and SCONE™ are investigational devices and are limited by US federal law to investigational use only. The Food and Drug Administration has not yet reviewed the safety and effectiveness of SCIP™ or SCONE™. SpineX has not yet determined the most effective method of timing for therapy and is currently investigating these parameters in ongoing clinical trials.
In this episode, Dr Dante Yeh is joined by Casey Allen, MD, from the Institute of Surgery, Division of Surgical Oncology, Allegheny Health Network, Pittsburgh, Pennsylvania. They discuss Dr Allen's recent study, which found that widespread adoption of the fecal immunochemical test for noninvasive colorectal cancer screening could lead to substantial cost savings. This carries major value implications for a large population health system. Disclosure Information: Dr Allen has nothing to disclose. Dr Yeh receives author royalties from UpToDate, advisory panel/training honoraria from Takeda Pharmaceuticals, and advisory panel honoraria from Baxter, Eli Lilly, and Fresenius Kabi. To earn 0.25 AMA PRA Category 1 Credits™ for this episode of the JACS Operative Word Podcast, click here to register for the course and complete the evaluation. Listeners can earn CME credit for this podcast for up to 2 years after the original air date. Learn more about the Journal of the American College of Surgeons, a monthly peer-reviewed journal publishing original contributions on all aspects of surgery, including scientific articles, collective reviews, experimental investigations, and more. #JACSOperativeWord
Dr. Jeanine Downie discusses non-Invasive fat removal, including technology evolution, treatment approach, results, and combination therapies.
Welcome to Episode 26 of “The 2 View,” the podcast for EM and urgent care nurse practitioners and physician assistants! Show Notes for Episode 26 of “The 2 View” – Save time charting & code accurately, dementia, PE in pregnancy, and the PCN shortage. PCN Shortage Ault, A. FDA Drug Shortages. Current and Resolved Drug Shortages and Discontinuations Reported to FDA. FDA issues new rule on drug shortages. Community Oncology, 9(1), 34. U.S. Food & Drug. Published April 26, 2023. Accessed May 9, 2023. https://doi.org/10.1016/j.cmonc.2011.12.003 Bendix, A. Shortage of penicillin limits access to the go-to drug for syphilis. NBC News. Published April 27, 2023. Accessed May 9, 2023. https://www.nbcnews.com/health/health-news/shortage-penicillin-limits-access-go-drug-syphilis-rcna81777 Global shortages of penicillin. Shortages of benzathine penicillin. Global Sexually Transmitted Infections Programme. World Health Organization. Who.int. Accessed May 9, 2023. https://www.who.int/teams/global-hiv-hepatitis-and-stis-programmes/stis/treatment/shortages-of-penicillin Dementia Alzheimer's Disease Fact Sheet. Alzheimer's Disease and Related Dementias: Basics of Alzheimer's Disease and Dementia. National Institute on Aging. Accessed May 9, 2023. https://www.nia.nih.gov/health/alzheimers-disease-fact-sheet Home. Alzheimer's Disease and Dementia. Alzheimer's Association. Accessed May 9, 2023. https://www.alz.org/ Silbert, L, Erten-Lyons, D. Memory Loss, Confusion in a 51-Year-Old Fired From Her Job. Medscape. Published March 2, 2023. Accessed May 9, 2023. https://reference.medscape.com/viewarticle/850363 PE in Pregnancy Negaard M. YEARS Algorithm for pulmonary embolism (PE). MDCalc. Accessed May 9, 2023. https://www.mdcalc.com/calc/4067/years-algorithm-for-pulmonary-embolism-pe Stals MAM, Moumneh T, Ainle FN, et al. Noninvasive diagnostic work-up for suspected acute pulmonary embolism during pregnancy: a systematic review and meta-analysis of individual patient data. J Thromb Haemost. 2023;21(3):606-615. NIH: National Library of Medicine: National Center for Biotechnology Information. PubMed. Published December 22, 2022. Accessed May 9, 2023. https://pubmed.ncbi.nlm.nih.gov/36696189/ Thromboembolism in Pregnancy. ACOG: The American College of Obstetricians and Gynecologists. Acog.org. Practice Bulletin, Number 196. Published July 2018. Accessed May 9, 2023. https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2018/07/thromboembolism-in-pregnancy Charting & Coding 2023 Emergency Department Evaluation and Management Guidelines. ACEP: American College of Emergency Physicians. Acep.org. Last Updated: October 2022. Accessed May 9, 2023. https://www.acep.org/administration/reimbursement/reimbursement-faqs/2023-ed-em-guidelines-faqs American Medical Association. 2023 Emergency Medicine Coding Guide. MDCalc. Accessed May 9, 2023. https://www.mdcalc.com/calc/10454/2023-emergency-medicine-coding-guide CPT Evaluation and Management (E/M) Code and Guideline Changes. AMA: American Medical Association. Ama-assn.org. Accessed May 9, 2023. https://www.ama-assn.org/system/files/2023-e-m-descriptors-guidelines.pdf ICD-10-CM Coding for Social Determinants of Health. AHA: American Hospital Association – Advancing Health in America. Aha.org. Published January 2022. Accessed May 9, 2023. https://www.aha.org/system/files/2018-04/value-initiative-icd-10-code-social-determinants-of-health.pdf Level of MDM (based on 2 of 3 elements of MDM) number and complexity of problems addressed. ACEP: American College of Emergency Physicians – Advancing Emergency Care. ERCODER. Acep.org. Accessed May 9, 2023. https://www.acep.org/siteassets/sites/acep/media/reimbursement/acep---2023-ed-mdm-grid.pdf Recurring Sources Center for Medical Education. Ccme.org. http://ccme.org The Proceduralist. Theproceduralist.org. http://www.theproceduralist.org The Procedural Pause. Emergency Medicine News. Lww.com. https://journals.lww.com/em-news/blog/theproceduralpause/pages/default.aspx The Skeptics Guide to Emergency Medicine. Thesgem.com. http://www.thesgem.com Trivia Question: Send answers to 2viewcast@gmail.com Be sure to keep tuning in for more great prizes and fun trivia questions! Once you hear the question, please email us your guesses at 2viewcast@gmail.com and tell us who you want to give a shout-out to. Be sure to listen in and see what we have to share!
When applying a device to deliver noninvasive ventilation (e.g., CPAP or BiPAP) to a patient, many providers forget to pay attention to one of the most critical aspects of using these lifesaving devices: the mask that assists to deliver oxygen at the flow rate set on the device. Read the full article here on EMS Airway.
Although the variety of noninvasive interfaces for pediatric patients has grown in the past 10 years, they are still limited. Pediatric interfaces are typically scaled down from adult to child sizes, which does not consider the contours of a growing child's face, causing poor fit in patients of certain ages. Donald S. Prough, MD, FCCM, was joined by Natalie Napolitano, MPH, RRT-NPS, during the 2023 Critical Care Congress to discuss how clinicians' need to have the right equipment for their patients led to a device development project using 3D imaging that obtained sample sizes from various age groups to bridge the fit gap and lessen pressure point injury among pediatric patients. Natalie Napolitano, MPH, RRT-NPS, is a respiratory therapist and research clinical specialist at the Children's Hospital of Philadelphia in Philadelphia, Pennsylvania, USA.
Hello, and welcome to Beauty and the Biz where we talk about the business and marketing side of plastic surgery and how to Dr. Katz has 50 lasers and devices. I'm your host, Catherine Maley, author of Your Aesthetic Practice – What your patients are saying, as well as consultant to plastic surgeons, to get them more patients, more profits and stellar reputations. Now, today's episode is called "50 Lasers and Devices — with Bruce Katz, MD". Non-surgical rejuvenation is a big deal. The global non-invasive aesthetic treatment market size was valued at 61.2 billion in 2022 and is projected to expand at a compound annual growth rate of 15.40% from 2023 to 2030. (Resource: Grandviewresearch.com) And, the most popular non-surgical procedures are Botox, Fillers, Fat Reduction, Skin Tightening, Skin Care Treatments. So, I thought it would be interesting to have Dr. Bruce Katz, MD on the Beauty and the Biz podcast. Dr. Katz is a board-certified dermatologist who practices dermatology, cosmetic, and laser surgery in Manhattan, Queens and worldwide. Dr. Katz is a leading innovator and researcher performing clinical trials on advanced laser technology, cosmetic surgery, body contouring & dermatology. We talked about the plethora of non-SX technologies entering the marketplace and what else is coming down the pike. Very exciting! He also had great advice for those buying technology, so you actually make money from it (that was promised from the salesperson) ;-) Visit Dr. Katz's website P.S. Please review!
Ticiana De Francesco, MD, shares an update on the first-in-human experience with femtosecond laser image-guided high-precision trabeculotomy, or FLIGHT (ViaLase), as covered in an article she coauthored with Iqbal Ike K. Ahmed, MD, FRCSC, for an upcoming issue of Glaucoma Today. Dr. De Francesco describes the new procedure and how it could help expand options for safe and effective glaucoma intervention.
We are officially launching our Patreon next week on DNA Day, April 25th! To celebrate the 70th anniversary of the discovery of the structure of DNA and 20th anniversary of the completion of the human genome. By becoming a Patreon supporter you can receive benefits like joining our exclusive genetics book/movie club, mentorship sessions with me, even being on an episode of DNA Today! If you sign up as a Patreon supporter in the next month (by May 25th) we will throw in an extra physical gift, a piece of DNA Today merch. We launch on DNA Day (April 25th) so you can celebrate our genetics holiday by becoming one of our first patrons then! As a prenatal genetic counselor, our host, Kira Dineen, is very intrigued to learn all about the new advances in non-invasive prenatal screening or NIPS. To see what's new in at-home NIPS we are joined by experts from Juno Diagnostics (JunoDx), Katie Sagaser and Allison Rodgers!Katie Sagaser is the Director of Genetic Counseling at Juno Diagnostics. Katie's team provides telehealth, prenatal genetic counseling services for patients undergoing Juno's Hazel™ Non-Invasive Prenatal Screen – the first at-home, capillary-based NIPS for fetal aneuploidy. Prior to joining JunoDx, Katie was an assistant professor of Gynecology & Obstetrics in the Division of Maternal Fetal Medicine at the Johns Hopkins University School of Medicine. Katie's professional interests center on equitable access to genetic testing and access to comprehensive reproductive health care throughout the lifespan. Most recently, she was the lead author on NSGC's Practice Guidelines for Expanded (Equitable) Carrier Screening. A member of both the Society for Maternal Fetal Medicine Reproductive Health Advisory Group and NSGC's Public Policy Committee, Katie is also actively engaged in public policy work surrounding reproductive health and genetics. At Juno, Katie is passionate about using social and digital media to scale access to high-quality information on genetics and reproductive medicine.Dr. Allison Rodgers is a double board-certified OB-GYN and fertility doctor. She is currently the Director of Education at Fertility Centers of Illinois, a US Fertility Practice; additionally, she serves on the Clinical Advisory Board for Juno Diagnostics. Dr. Rodgers' personal experiences with secondary infertility and pregnancy loss inform her unique insights into reproductive medicine, contributing to compassionate and individualized patient care. She is published in top medical journals covering endometriosis, tubal factor infertility, in vitro fertilization, and donor sperm. Her special interests include in-vitro fertilization, endometriosis, polycystic ovarian syndrome, unexplained infertility, recurrent pregnancy loss, premature ovarian insufficiency, LGTBQIA+ fertility, reciprocal IVF, and transgender fertility. She completed her residency at Case Western Reserve-Metrohealth Medical Center Cleveland Clinic, followed by a fellowship at the University of Texas Health Science Center in San Antonio. You may recognize Dr. Rodgers from Tik Tok and Instagram where she shares fertility education with more than 1.3 million followers!On This Episode We Discuss:The inspiration behind JunoDx and their goal/missionWhat drew Katie and Allison to JunoDxHow JunoDx's technology/approach differs from other companies to successfully perform NIPS on a much smaller sample volumeHow does Juno's at-home approach to sample collection for NIPS increases accessibility, particularly those in underserved or remote areasThe difference between JunoDx's 2 NIPS, Hazel and BirchDetermining sex of the baby with Birch NIPSConditions included in the more comprehensive Hazel screeningThe process of ordering Hazel or Birch NIPS, collecting the sample, to learning the resultsThe positive predictive value and negative predictive values of the tests, what these values mean, and how they compare to other NIPS and other at-home NIPSThe evolution and future of at-home NIPS tests, particularly related to advancements in technology and genetic testingTo learn more about Juno Dx, visit their website and Youtube and Pinterest pages. You can also follow Juno Dx on Twitter, Facebook, Instagram and TikTok. And be sure to follow Dr. Rodgers on Tik Tok and Instagram, and Katie Sagaser on Twitter and Instagram!Further Reading:Capillary blood collection: exploring a new method to promote noninvasive prenatal screening access "An exploration of methods to enable equitable access to non-invasive prenatal screening""Optimizing blood collection, transport and storage conditions for cell free DNA increases access to prenatal testing""Noninvasive prenatal detection of sex chromosomal aneuploidies by sequencing circulating cell-free DNA from maternal plasma""Women In Wellness: Katie Sagaser of JunoDx On The Five Lifestyle Tweaks That Will Help Support People's Journey Towards Better Wellbeing" Stay tuned for the next new episode of DNA Today on April 28th, 2023, where we'll be going back in time to explore the history of the genetic counseling field. We are focusing on the first annual conference for genetic counselors which was in 1981, 54 years ago! Joining us for this conversation are two rockstars in the field of GC, Debra Collins & Michelle Fox! New episodes are released every Friday. In the meantime, you can binge over 230 other episodes on Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Today”. Episodes since 2021 are also recorded with video which you can watch on our YouTube channel. DNA Today is hosted and produced by Kira Dineen. Our social media lead is Corinne Merlino. Our video lead is Amanda Andreoli. Our Outreach Intern is Sanya Tinaikar. Our Social Media Intern is Kajal Patel. And our Graphic Designer Ashlyn Enokian.See what else we are up to on Twitter, Instagram, Facebook, YouTube and our website, DNAToday.com. Questions/inquiries can be sent to info@DNAtoday.com. Are you interested in the rapidly growing field of genetics and want to learn more about clinical genetics, molecular genetics, and laboratory science? Then you should check out the Genetic Assistant Online Training Program at Johns Hopkins University School of Medicine!By taking part in the program, you will be joining both national and international learners with the same passion for genetics. Interact directly with your Johns Hopkins instructors and fellow learners throughout the program. Limited spots are available for the summer cohort starting June 5th, 2023. Click here for more information. (Sponsored)Want to become a genetic counselor? Looking for ways to engage with the field and boost your resume for grad school applications? Then you should check out Sarah Lawrence's “Why Genetic Counseling Wednesday Summer Series”! Every Wednesday this June (plus the last Wednesday in May) Sarah Lawrence is hosting a series where you can interact through Zoom with genetic counselors from different specialties. It kicks off on May 31st! You can sign up at SLC.edu/DNAtoday. Again visit SLC.edu/DNAtoday to register to level up your resume for applications in the fall. (Sponsored)As many of you know through podcasting I have become an entrepreneur including consulting for other podcasts. Since I don't have a business degree I have learned a lot through podcasts like Porch Talks. The inspiration to start this show was from the host Melissa Bradley who wanted to inform, instruct, and inspire fellow entrepreneurs, especially in people who identify as women, people of color, immigrants, veterans, people with disabilities, and folks in the LGBTQIA+ community (which drew me in initially). So if you are thinking about starting a business or just love hearing stories about how businesses grow, Porch Talks is for you. (Sponsored)
See all the Healthcasts at https://www.biobalancehealth.com/healthcast-blog If you are over 50 you have probably wished that you could have a face lift to bring you back to how you looked in your 20s or 30s. As an owner of a Medical Esthetic Spa named BioBalance Skin®, and because I am 68 myself, I have spent years looking for a facial treatment that would get the results of a surgical face lift, but without the pain, surgery and downtime. Because of the EmFace, I have finally found what I was looking for so I bought it! It is called EM-Face, kin is the first medical spa to offer this treatment that makes facelifts a thing of the past. The EM Face is not only unique because the results of the EmFace are amazing, but it is also unique because it isn't painful, it doesn't require many treatments (EMFace series is 4-6 treatments, one per week), and does not require anesthesia, there is no down time, no loss of time from work, and you are not at the mercy of a surgeon's skill to make you look like yourself at a younger age, instead of a young stranger (think Sharon Stone). The EmFace treatment is done in our Medical Spa, and each treatment takes 30 minutes. There is no operating room or anesthesia needed and it takes 4-6 sessions 30-minutes long , painless treatments that you don't even have to get undressed for! After your treatment you can go right out in the world without bruising or any sign that you had a face lifting procedure. How does the EmFace work? It uses electrical stimulation of the facial muscles to pull your facial skin up toward your temples, and it also tightens the facial skin so it literally makes your skin smooth and removes wrinkles! Skin tone and muscle tone are improved and wrinkles disappear. …A face lift doesn't improve your skin tone and it only smooths deep wrinkles. Leaves no evidence of having a lifting procedure except that over the following 3 months you look progressively younger. This is an advantage if you don't want your friends to know that you had anything done to make you look younger. A face lift is obvious and it is hard to hide the fact that you had a major procedure to regain a youthful looking face. How long does it last? A Face Lift lasts about 10 years depending on the thickness and tone of your skin, as well as your age when you have the surgery. EmFace generally requires one maintenance treatment a year to maintain the “lift” indefinitely. Cost comparison? EM-face 4 treatments costs around $2,800 and 6 treatments cost $3600 at BioBalance Skin®and that's it!. A facelift surgeon can charge t up to $100,000 for his or her services. Then you have to add the additional costs of the operating room + the cost of the surgical assistant + supplies and usually you have to pay for one night in the surgery center. For a facelift, plan on paying over $150,000 total (assuming you have no complications) vs a total charge of $2,800-$3,600 for an EMSCULPT facelift. Oh, I forgot to add the value of your time off from your job which can be 3 months after a facelift, before you want be seen in public. Why does a face lift prevent you from showing your face right away? Facelift Surgery on the face involves dissecting the skin away from the muscle and bones of the face, pulling the skin up toward your temples, trimming off extra skin and then closing the incisions with suture. This massive dissection causes a large amount of swelling and bruising, requiring drains placed in your face, for weeks. This damage lasts a long time and is PAINFUL! It generally causes patients to remain housebound until they completely recover, which can be months. EMFace causes none of these side effects and complications, so you can go out in public, or back to work right afterwards with a “glow”, and no sign that you had anything more than a facial. What are the comparable risks? The risks of a facial surgery of any kind are dramatic…damage to the facial nerve may not be recoverable, making you unable to smile or show expression on one side of your face. Surgery risks are always numerous and most surgeries include the complications of anesthesia, even death, infection, bruising, non-healing, nerve damage scar formation and facial drooping. What should I do to prepare for either of these treatments for good results? Replace your testosterone (improves healing), and estradiol (improves texture and tone of your facial skin. Topical Skin Care, medical grade, (eg. Skinceuticals products) that stimulates the stem cells of your skin to grow and smooth the texture preparing for healing and tightening. Replace your estrogen and testosterone if you are over 45, 4- 6 months before the “lift”. Eat a high protein diet (more than half your weight in grams of protein/day) Stay hydrated with water and sometimes electrolytes. Lose as much weight as possible before the procedure. Get monthly hydra-facials and or micro-needling to prep your skin Take daily collagen supplementation in your coffee or tea Take healing vitamins: Vitamin D 5,000 u/day, Vitamin Methyl B12 and Methyl-folate, Vitamin A 10,000-25-000 u/day, Vitamin C 1000 mg/day at the very least. To help you make a decision, I have to tell you a little secret about what a facelift doesn't do.: a facelift doesn't take the place of getting filler every 6-12 months; A facelift doesn't take the place of botox of other neurotoxin. After a face lift you will still need regular skin peels and hydrafacials, exfoliation, and rejuvenation of the face and neck with laser or micro-needling! A facelift JUST LIFTS! EmFace lifts sagging facial skin, smooths the skin on the face and forehead, and improves texture and tone of the facial skin while removing wrinkles and stimulating underlying facial muscles to become the same size and shape as when they were younger! You may notice that you don't need a neurotoxin as often as you did before the EmFace. You may not need as much superficial filler to erase superficial wrinkles or dimpling. EmFace also lifts the corners of your mouth so the downturn of the corners of your mouth are not as obvious, in fact the corners of your mouth actually turn up like they did when you were younger. This is what you've been waiting for! I know it was what I was waiting for…the EmFace machine wasn't inexpensive, so the treatments using EmFace are not cheap….but they are drastically more affordable and less dangerous than a facelift! I have finished my series and am happy that I no longer dread the time and risk of having a facelift in the future.
Noninvasive respiratory support is an important modality utilized in the pediatric critical care setting to treat respiratory failure without the use of an artificial airway. On today's discussion, pediatric critical care fellow, Dr. John-David Bruce joins pediatric hospitalist, Dr. Brynn Ehlers and Dr. Gene Fisher who is a pediatric intensivist that serves as the division chief of Pediatric Critical Care unit at the Children's Hospital of Georgia. After listening to this podcast, learners should be able to: 1. Recognize different types of noninvasive respiratory support 2. Have an understanding of basic settings involved in the different modes of noninvasive respiratory support 3. Discuss conditions that are most ideal for noninvasive respiratory support 4. Recognize when it is necessary to escalate to a higher mode of respiratory support 5. Common complications of noninvasive respiratory support and how do you treat them. FREE CME Credit (requires free sign-up): https://mcg.cloud-cme.com/course/courseoverview?P=0&EID=19507 References: Amin, R, & Arca, MJ. Feasibility of non-invasive neurally adjusted ventilator assist after congenital diaphragmatic hernia repair. Journal of Pediatric Surgery, 2019;54(3):434-438. Coletti, KD, Bagdure, DN, Walker, LK, Remy, KE, & Custer, JW. High-flow nasal cannula utilization in pediatric critical care. Respiratory Care, 2017;62(8):1023-1029. Desai, JP, & Moustarah, F. Pulmonary Compliance. StatPearls Publishing. 2021. https://www.ncbi.nlm.nih.gov/books/NBK538324/ Fedor, KL. Noninvasive respiratory support in infants and children. Respiratory Care, 2017;62(6):699-717. Franklin, D, Babl, FE, & Schlapbach, LJ, et al. A randomized trial of high-flow oxygen therapy in infants with bronchiolitis. The New England Journal of Medicine, 2018;378:1121-1131. Intagliata, S, Rizzo, A, & Gossman, WG. Physiology, Lung Dead Space. StatPearls Publishing. 2020. https://www.ncbi.nlm.nih.gov/books/NBK482501/ Morrison, WE, Nelson McMillan, KL, & Shaffner, DH. (Eds.). Roger's Handbook of Pediatric Intensive Care (5th ed.). 2017. Wolters Kluwer. Najaf-Zadeh A, & Leclerc F. Noninvasive positive pressure ventilation for acute respiratory failure in children: a concise review. Ann Intensive Care. 2011;1(1):15. doi:10.1186/2110-5820-1-15 Oymar, K, & Bardsen, K. Continuous positive airway pressure for bronchiolitis in a general paediatric ward; a feasibility study. BMC Pediatrics. 2014;14:122. Pope, JF, & Birnkrant, DJ. Noninvasive ventilation to facilitate extubation in a pediatric intensive care unit. Journal of Intensive Care Medicine. 2000;15(2):99-103. Storre, JH, Bohm, P, Dreher, M, & Windisch, W. Clinical impact of leak compensation during non-invasive ventilation. Respiratory Medicine. 2009;103(10):1477-1483. Silver AH, Nazif JM. Bronchiolitis. Pediatr Rev. 2019;40(11):568-576. doi:10.1542/pir.2018-0260
On today's Friday update: the Maryland Attorney General's office is investigating heinous accusations that at least 158 priests abused and even physically “tortured” 600 or more child victims in the DMV area. Plus, breakthrough in Alzheimer's research — something called gamma wave entrainment, assisted by machine learning and AI algorithms, could “jumpstart” the brain into regaining previous healthy activity. Researchers believe noninvasive gamma entrainment sequences could restore previous brain function to those suffering from Alzheimer's and other cognitive disorders. More research is needed, of course. Research links:Noninvasive brain wave treatment reduces Alzheimer's pathology, improves memory in mice https://www.nia.nih.gov/news/noninvasive-brain-wave-treatment-reduces-alzheimers-pathology-improves-memory-mice Gamma Oscillations in Alzheimer's Disease and Their Potential Therapeutic Role https://pubmed.ncbi.nlm.nih.gov/34966263/ https://amazon.com/author/davidseaman — Read “Sacred West” and the other original research books FULCRUM has released over the years!https://paypal.me/davidseaman for tips
Maria Zannes, Founder and CEO of bioAffinity Technologies, has developed a noninvasive diagnostic test to screen for early-stage lung cancer. The test uses porphyrin to label cells to find cell populations with cancer cells. Using mucus from the lungs, this is a second test for people who are at high risk, giving them a chance to avoid more invasive procedures to determine their risk level and if they have lung cancer. Maria explains, "The combination of being able to determine that cancer is present in the lungs with our test, coupled with the noninvasive nature of the test itself really spoke to me. Having a test for early detection of lung cancer where the treatment can be so much more effective and people can live so much longer and healthier lives is compelling." "It's very simple for the patient and the doctor. The patient would go in, let's say they had a positive low-dose CT, they weren't sure, and the physician would then give the patient a small box. It's a 5x5 box with a little collection cup inside. We have a patient coach, an individual who calls the patient, and helps them to provide a sample, often early in the morning. People out of a shower start to cough up a little bit of mucus." "The results tell the physician whether the patient is at high risk or has lung cancer or does not, but also gives them a numerical score, so the physician himself or herself has a little bit more to go on than just a yes or no answer." @bioAffinity #LungCancer #CancerDiagnostic #Medtech #Biotech #CancerTreatment #CancerDiagnosis bioaffinitytech.com Download the transcript here
Maria Zannes, Founder and CEO of bioAffinity Technologies, has developed a noninvasive diagnostic test to screen for early-stage lung cancer. The test uses porphyrin to label cells to find cell populations with cancer cells. Using mucus from the lungs, this is a second test for people who are at high risk, giving them a chance to avoid more invasive procedures to determine their risk level and if they have lung cancer. Maria explains, "The combination of being able to determine that cancer is present in the lungs with our test, coupled with the noninvasive nature of the test itself really spoke to me. Having a test for early detection of lung cancer where the treatment can be so much more effective and people can live so much longer and healthier lives is compelling." "It's very simple for the patient and the doctor. The patient would go in, let's say they had a positive low-dose CT, they weren't sure, and the physician would then give the patient a small box. It's a 5x5 box with a little collection cup inside. We have a patient coach, an individual who calls the patient, and helps them to provide a sample, often early in the morning. People out of a shower start to cough up a little bit of mucus." "The results tell the physician whether the patient is at high risk or has lung cancer or does not, but also gives them a numerical score, so the physician himself or herself has a little bit more to go on than just a yes or no answer." @bioAffinity #LungCancer #CancerDiagnostic #Medtech #Biotech #CancerTreatment #CancerDiagnosis bioaffinitytech.com Listen to the podcast here
In this episode we are learning about UNITY Screen non-invasive prenatal testing (NIPT) for recessive conditions. Joining our host Kira Dineen are two experts from BillionToOne, the CEO Oguzhan Atay and the Senior Director of Medical Affairs, Jen Hoskovec. Stay tuned for our part two about their new fetal antigen NIPT! Oguzhan Atay, PhD, BillionToOne co-founder, has led the company since its inception and raised more than $200M in funding including from venture capital funds and investors who previously invested in tech companies such as SpaceX, Box, Spotify, Palantir, Braintree, and biotech companies such as Counsyl, WebMD, and Omada Health! Oguzhan received his PhD from Stanford University, where his work was published on the Cover of Cell Systems. He graduated summa cum laude and Phi Beta Kappa from Princeton University with a bachelor's in molecular biology and minors in physics, computer science, and applied mathematics.Jennifer Hoskovec, MS, CGC, joined BillionToOne as the Senior Director of Medical Affairs in July 2020. As a certified genetic counselor with over 17 years of clinical experience, Jen is committed to ensuring patients and providers are supported and educated about the options and utility of prenatal testing. Jen joined BillionToOne after 17 years as a prenatal genetic counselor at UTHealth where she led a team of genetic counselors providing patient care in MFM clinics across the city of Houston. Jen has extensive volunteer and leadership experience within national societies such as American College of Obstetrics and Gynecology and National Society of Genetic Counselors. She served as president of NSGC in 2014. Jen earned her MS in genetic counseling from the University of Texas Health Science Center in Houston and her Bachelor of Science in Biology with a minor in Chemistry from Truman State University.On this episode we discuss:Noninvasive prenatal testing (NIPT)What is UNITY Screen and why the name UNITY?Recessive conditions included in UNITY ScreenInformation included in a UNITY NIPT reportTest specificity and sensitivity differences between ethnicitiesHow typical carrier screening flows work differently with UNITYWhy it is helpful to have information regarding the chance a pregnancy is affected by a recessive conditionBillionToOne's plans to include more recessive conditions in UNITY ScreenTo stay up to date with the latest developments at BillionToOne, follow them on Twitter, facebook and LinkedIn. You can also connect with our guest, Jen Hoskovec on Twitter. Stay tuned for the next new episode of DNA Today on February 24th, 2023 where we continue this NIPT discussion with Jen Hoskovec focusing on screening for antigens. New episodes are released every Friday. In the meantime, you can binge over 220 other episodes on Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Today”. Episodes since 2021 are also recorded with video which you can watch on our YouTube channel. DNA Today is hosted and produced by Kira Dineen. Our social media lead is Corinne Merlino. Our video lead is Amanda Andreoli. Our outreach Intern is Sanya Tinaikar. Our Social Media Intern is Kajal Patel. And our Graphic Designer Ashlyn Enokian.See what else we are up to on Twitter, Instagram, Facebook, YouTube and our website, DNAToday.com. Questions/inquiries can be sent to info@DNAtoday.com. If you've been listening to DNA Today for a while, you probably know I am also a full time prenatal genetic counselor. Between that job, this podcast, and being a producer/host of other podcasts, I am pretty busy! To keep my energy up and stay productive I drink a decent amount of coffee. The new coffee I'm drinking is from Four Sigmatic. I'm really picky about my coffee, it's got to be bold, not watery. And I've been really happy with Four Sigmatic. Here's the difference from other coffees, it includes mushrooms, which I know sounds bizarre. I will admit I was hesitant, but you get health benefits and don't taste it. I like the immune system boost, as I often get sick in the winter months. So we teamed up with Four SIgmatic to get you 30% off using promo code “DNATODAY” redeem it at FourSigmatic.com, again that's FourSigmatic.com using code “DNATODAY” for 30% off! And let me know if you like it too! (Sponsored)Which drug do you prescribe for your HER2+ cancer patients? For the first time in history TruGene Diagnostics (formerly Blueprint Diagnostics) informs you which of the 3 leading cancer drugs your patient is sensitive to and resistant to. TruGene Diagnostics knows the functional effect of EVERY mutation in the TK region of HER2 Gene. And knows the functional effect with and without the 3 most common drugs present. Thus allowing you to match the best drug to the patient. Unlock the best drug for your patients with HER2+ cancer using TruGene Diagnostics. Check it out at TruGeneDiagnostics.com. Stay tuned for our interview with them! (Sponsored)
Noninvasive “tweakments” like DiamondGlow facials, Morpheus8, and the Moxi laser are gaining popularity with people who say they're “high maintenance to be low maintenance.” Meaning: Can getting some cosmetic procedures now mean less makeup, less skincare, and less upkeep in the long run? Let's discuss! After that: The FDA's authority over cosmetics regulations is expanding, there's a correlation between drinking sugary beverages and hair loss, and Jenn geeks out in the science corner. Plus, a listener raises a wand to Lucine, a shop that sources beautiful accessories from around the world, and we are officially obsessed.Sponsor links & discount codes: shopmy.us/collections/31511Episode recaps with links: fatmascara.com/blogProducts mentioned on Ep. 471: shopmy.us/collections/public/109386Private Facebook Group: Fat Mascara Raising a WandSocial media: @fatmascara, @jessicamatlin, @jenn_editSubmit a "Raise A Wand" product recommendation and be featured on the show: email info@fatmascara.com or leave a voicemail at 646-481-8182 Become a member at https://plus.acast.com/s/fatmascara. Hosted on Acast. See acast.com/privacy for more information.
About our Guest:Dr. Yehya is a graduate of the University of California at Berkeley and the University of California at Los Angeles School of Medicine. After completing pediatrics training at Children's Hospital of Los Angeles, he completed his pediatric critical care fellowship at Children's Hospital of Philadelphia (CHOP), and joined the faculty after graduation in 2011. He is currently an Assistant Professor of Anesthesiology and Critical Care and Pediatrics at the Perelman School of Medicine at the University of Pennsylvania and an attending physician in the pediatric intensive care unit at CHOP.Dr. Yehya's research interests encompass all aspects of pediatric respiratory failure, with a particular emphasis on pediatric acute respiratory syndrome (ARDS) and mechanical ventilation. ARDS consists of sudden, severe flooding of the lungs in response to an inflammatory insult causing difficulty breathing, frequently requiring mechanical ventilation. Sepsis is a leading cause of ARDS in children. His long-term goal is better characterization of ARDS in children and to test therapies designed to improve outcomes. His NIH-funded work is assessing the utility of specific plasma biomarkers in pediatric ARDS, with subsequent proteomic characterization and testing in pre-clinical models. Dr. Yehya has several active studies involving biomarkers, clinical epidemiology, and pathophysiological mechanisms in the field of pediatric ARDS, and is involved in several multicenter and multinational collaborations.Objectives:After listening to this episode, learners should be able to:Understand the role of heated high-flow nasal cannula and non-invasive mechanical ventilation in the management of pediatric acute respiratory distress syndrome (PARDS).Recognize the potential for patient self-inflicted lung injury in PARDS.Recognize high-risk situations when non-invasive mechanical ventilation is relatively contraindicated in favor of intubation and mechanical ventilation.Acknowledgement:Thank you to Dr. Nick Bartel for his help in creating learning objectives for this series.How to support PedsCrit:Please rate and review on Spotify and Apple Podcasts!Donations are appreciated @PedsCrit on Venmo , you can also support us by becoming a patron on Patreon. 100% of funds go to supporting the show.Thank you for listening to this episode of PedsCrit. Please remember that all content during this episode is intended for educational and entertainment purposes only. It should not be used as medical advice. The views expressed during this episode by hosts and our guests are their own and do not reflect the official position of their institutions. If you have any comments, suggestions, or feedback-you can email us at pedscritpodcast@gmail.com. Check out http://www.pedscrit.com for detailed show notes. And visit @critpeds on twitter and @pedscrit on instagram for real time show updates.Selected references:PMID: 10793162PMID: 25693014.PMID: 15269312PMID: 30361119PMID: 17426195PMID: 31112383PMID: 25647235PMID: 19001507PMID: 32043986.PMID: 15671432. Support the show
Noninvasive prenatal screening (1:40), antibiotics in upper respiratory infections (3:50), posttraumatic stress disorder (10:30), people experiencing homelessness (13:20), deprescribing proton pump inhibitors (17:30), a new practice guideline for adults with hypertension (20:10), and our favorite holiday and winter ICD 10 codes (22:50).
(00:31) Could you each provide us a little bit about yourself and your background? Dr. Zheng, we'll start with you.(01:40) Dr. Mansfield, how about you?(02:07) Could you explain a little bit about the new biopsy test and the technology?(03:58) Which patients should have this testing and when should it be used?(06:44) What alternative test options are available and how would they compare to the Mayo complete cell-free DNA panel?(08:28) Can you go into a little more detail from a clinical practice perspective about how these tests are used?(10:16) Dr. Zheng, is there anything else you would like to add to this discussion?(10:53) Dr. Mansfield, is there anything else you would like to add to this discussion?
Come along with us to figure out how heating up testicles could be an effective male contraceptive, how ultrasounds might help us cure Type 2 diabetes, and how a robotic fish might soon clean our oceans.Heating up testes isn't what you think.“Heating Up Testicles Could Solve a Major Male Contraceptive Issue” by Jeffrey Mohttps://www.inverse.com/mind-body/heating-up-testicles“Magnetic Testis Targeting and Magnetic Hyperthermia for Noninvasive, Controllable Male Contraception via Intravenous Administration” by Weihua Ding, et al.https://pubs.acs.org/doi/10.1021/acs.nanolett.1c02181Type 2 diabetes potential cure.“Diabetes Successfully Treated Using Ultrasound in Preclinical Study” by Rich Haridyhttps://newatlas.com/medical/focused-ultrasound-prevents-reverses-diabetes-ge-yale/“Treating Diabetes Without Drugs? Novel Non-Pharmacological Treatments on the Horizon” by Jane E. Deehttps://medicine.yale.edu/news-article/treating-diabetes-without-drugs-novel-non-pharmacologic-treatments-on-the-horizon/“Ultrasound: The Future of Diabetes Treatment?” by Tim Newmanhttps://www.medicalnewstoday.com/articles/325160Robotic fish are the future.“Scientists unveil bionic robo-fish to remove microplastics from seas” by Sofia Quagliahttps://www.theguardian.com/environment/2022/jun/22/scientists-unveil-bionic-robo-fish-to-remove-microplastics-from-seas“Robust, Healable, Self-Locomotive Integrated Robots Enabled by Noncovalent Assembled Gradient Nanostructure” by Yuyan Wang, Gehong Su, Jin Li, Quanquan Guo, Yinggang Miao, and Xinxing Zhanghttps://www.theguardian.com/environment/2022/jun/22/scientists-unveil-bionic-robo-fish-to-remove-microplastics-from-seas#:~:text=is%20described%20in-,a%20research%20paper,-in%20the%20journalFollow Curiosity Daily on your favorite podcast app to get smarter with Calli and Nate — for free! Still curious? Get exclusive science shows, nature documentaries, and more real-life entertainment on discovery+! Go to https://discoveryplus.com/curiosity to start your 7-day free trial. discovery+ is currently only available for US subscribers.Find episode transcripts here: https://curiosity-daily-4e53644e.simplecast.com/episodes/hot-testes-blasting-diabetes-robo-fish-cleans-ocean
The utilization of point-of-care ultrasound and other non-invasive cardiac output monitoring technologies varies because of knowledge, resource availability and cultural practices. In this Clinical Challenge in Surgery episode from the Surgical Critical Care team at Behind the Knife, we provide a brief history of the use of cardiac-output monitoring in the ICU, introduce a few clinical scenarios in the context of point of care ultra-sound and other less-invasive cardiac-output monitoring technologies. Learning Objectives: In this episode, we review the historical uses of central venous pressure monitoring, pulmonary-artery catheters and the more frequently utilized point-of-care-ultrasound (or POCUS) in managing complex ICU patients. We review the outcomes behind these technologies, describe the views and utility of POCUS, and introduce less-invasive or completely non-invasive ways to measure cardiac-output monitoring. Hosts: Brittany Bankhead, MD, MS (@BBankheadMD) is an Assistant Professor of Surgery at Texas Tech University Health Sciences Center. Ryan Dumas, MD, FACS (@PMH_Trauma_RPD) is an Assistant Professor of Surgery at the University of Southwestern Medical Center and Parkland Memorial Hospital. Caroline Park, MD, MPH, FACS (@CPark_MD) is an Assistant Professor of Surgery at the University of Southwestern Medical Center and Parkland Memorial Hospital. Links to Papers Referenced in this Episode: National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network, Wheeler AP, Bernard GR, Thompson BT, Schoenfeld D, Wiedemann HP, deBoisblanc B, Connors AF Jr, Hite RD, Harabin AL. Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med. 2006 May 25;354(21):2213-24. doi: 10.1056/NEJMoa061895. Epub 2006 May 21. PMID: 16714768. Yildizdas D, Aslan N. Ultrasonographic inferior vena cava collapsibility and distensibility indices for detecting the volume status of critically ill pediatric patients. J Ultrason. 2020 Nov;20(82):e205-e209. doi: 10.15557/JoU.2020.0034. Epub 2020 Sep 28. PMID: 33365158; PMCID: PMC7705480. Kircher BJ, Himelman RB, Schiller NB. Noninvasive estimation of right atrial pressure from the inspiratory collapse of the inferior vena cava. Am J Cardiol. 1990 Aug 15;66(4):493-6. doi: 10.1016/0002-9149(90)90711-9. PMID: 2386120. Marik PE, Cavallazzi R. Does the central venous pressure predict fluid responsiveness? An updated meta-analysis and a plea for some common sense. Crit Care Med. 2013 Jul;41(7):1774-81. doi: 10.1097/CCM.0b013e31828a25fd. PMID: 23774337. Acknowledgements: We would like to acknowledge Dr. Hassan Mashbari and the Department of Surgical Critical Care and Anesthesia at the Massachusetts General Hospital and Dr. Christopher Choi and the Department of Anesthesiology at the University of Texas Southwestern for their ultra-sound video contributions. Please visit behindtheknife.org to access other high-yield surgical education podcasts, videos and more.
© 2020-2025 Ivy Podcast Discovery LLC
